On July 21, 2016, Wang, Xuehai; Wu, Chengde; Xu, Yong; Shen, Chunli; Li, Li’e; Hu, Guoping; Yue, Yang; Li, Jian; Guo, Diliang; Shi, Nengyang; Huang, Lu; Chen, Shuhui; Tu, Ronghua; Yang, Zhongwen; Zhang, Xuwen; Xiao, Qiang; Tian, Hua; Yu, Yanping; Chen, Hailiang; Sun, Wenjie; He, Zhenyu; Shen, Jie; Yang, Jing; Tang, Jing; Zhou, Wen; Yu, Jing; Zhang, Yi; Liu, Quan published a patent.Name: 3,5-Dibromo-1-methylpyrazin-2(1H)-one The title of the patent was Btk inhibitor. And the patent contained the following:
Provided are a series of heterocyclic compounds as BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or pro-drug thereof. The experimental process involved the reaction of 3,5-Dibromo-1-methylpyrazin-2(1H)-one(cas: 87486-34-8).Name: 3,5-Dibromo-1-methylpyrazin-2(1H)-one
The Article related to heterocycle preparation btk inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Imidazoles and other aspects.Name: 3,5-Dibromo-1-methylpyrazin-2(1H)-one